EP. 1: Molecular Testing in Early and Advanced NSCLC
Solange Peters, MD, PhD, and Tony SK Mok, MD, delve into the importance of molecular testing for EGFR mutant non-small cell lung cancer, including guidelines and commonly found barriers.
EP. 2: Adjuvant Therapy for EGFR Mutant Early-Stage NSCLC: ADAURA
Drs Peters and Mok discuss adjuvant therapy for patients with early-stage EGFR mutant NSCLC and the impact of the ADAURA clinical trial on how we treat this disease.
EP. 3: ADAURA and Selecting Adjuvant Therapy in EGFR Mutant Early-Stage NSCLC
Dr Mok finishes our discussion on the ADAURA trial, and Dr Peters delves into selecting the right adjuvant therapy for a patient with early-stage EGFR mutant NSCLC.
EP. 4: Available Treatment Options for Patients With EGFR Mutant NSCLC
Tony SK Mok, MD, and Solange Peters, MD, PhD, relay the available treatment options for EGFR mutant NSCLC—both early and advanced stages.
EP. 5: Updates in the Treatment of EGFR Mutant Advanced-Stage NSCLC
Drs Mok and Peters explain the updates seen in the treatment landscape for EGFR mutant advanced-stage NSCLC.
EP. 6: Future Outlook of EGFR Mutant NSCLC
Solange Peters, MD, PhD, and Tony SK Mok, MD, discuss what they’re looking forward to in the future for treating both stages of EGFR mutant NSCLC and give advice to colleagues treating this disease.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512